Derman Basaran1, Shaina Bruce1, Emeline M Aviki1, Jennifer J Mueller1, Vance A Broach1, Karen Cadoo2, Robert A Soslow3, Kaled M Alektiar4, Nadeem R Abu-Rustum1, Mario M Leitao5. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. Electronic address: leitaom@mskcc.org.
Abstract
OBJECTIVES: The objective of our study was to assess survival among patients with uterine serous carcinoma (USC) undergoing sentinel lymph node (SLN) mapping alone versus patients undergoing systematic lymphadenectomy (LND). METHODS: We retrospectively reviewed patients undergoing primary surgical treatment for newly diagnosed USC at our institution from 1/1/1996-12/31/2017. Patients were assigned to either SLN mapping alone (SLN cohort) or systematic LND without SLN mapping (LND cohort). Progression-free (PFS) and overall survival (OS) were estimated using Kaplan-Meier method, compared using Logrank test. RESULTS: 245 patients were available for analysis: 79 (32.2%) underwent SLN, 166 (67.7%) LND. 132 (79.5%) in the LND cohort had paraaortic LND (PALND) versus none in the SLN cohort. Median age: 66 and 68 years in the SLN and LND cohorts, respectively (p>0.05). Proportion of stage I/II disease: 67.1% (n = 53) and 64.5% (n = 107) in the SLN and LND cohorts, respectively (p>0.05). Median follow-up: 23 (range, 1-96) and 66 months (range, 4-265) in the SLN and LND cohorts, respectively (p < 0.001). Two-year OS in stage I/II disease (n = 160, 60.1%): 96.6% (SE ± 3.4) and 89.6% (SE ± 2.2) in the SLN and LND cohorts, respectively (p = 0.8). Two-year OS in stage III disease (n = 77): 73.6% (SE ± 10.2) and 77.3% (SE ± 5.8) in the SLN and LND cohorts, respectively (p = 0.8). CONCLUSIONS: SLN mapping alone and systematic LND yielded similar survival outcomes in stage I-III USC. In our practice, the SLN algorithm has replaced systematic LND as the primary staging modality in this setting.
OBJECTIVES: The objective of our study was to assess survival among patients with uterine serous carcinoma (USC) undergoing sentinel lymph node (SLN) mapping alone versus patients undergoing systematic lymphadenectomy (LND). METHODS: We retrospectively reviewed patients undergoing primary surgical treatment for newly diagnosed USC at our institution from 1/1/1996-12/31/2017. Patients were assigned to either SLN mapping alone (SLN cohort) or systematic LND without SLN mapping (LND cohort). Progression-free (PFS) and overall survival (OS) were estimated using Kaplan-Meier method, compared using Logrank test. RESULTS: 245 patients were available for analysis: 79 (32.2%) underwent SLN, 166 (67.7%) LND. 132 (79.5%) in the LND cohort had paraaortic LND (PALND) versus none in the SLN cohort. Median age: 66 and 68 years in the SLN and LND cohorts, respectively (p>0.05). Proportion of stage I/II disease: 67.1% (n = 53) and 64.5% (n = 107) in the SLN and LND cohorts, respectively (p>0.05). Median follow-up: 23 (range, 1-96) and 66 months (range, 4-265) in the SLN and LND cohorts, respectively (p < 0.001). Two-year OS in stage I/II disease (n = 160, 60.1%): 96.6% (SE ± 3.4) and 89.6% (SE ± 2.2) in the SLN and LND cohorts, respectively (p = 0.8). Two-year OS in stage III disease (n = 77): 73.6% (SE ± 10.2) and 77.3% (SE ± 5.8) in the SLN and LND cohorts, respectively (p = 0.8). CONCLUSIONS: SLN mapping alone and systematic LND yielded similar survival outcomes in stage I-III USC. In our practice, the SLN algorithm has replaced systematic LND as the primary staging modality in this setting.
Authors: Alessandro Buda; Maria Luisa Gasparri; Andrea Puppo; Liliana Mereu; Elena De Ponti; Giampaolo Di Martino; Antonia Novelli; Saverio Tateo; Michael Muller; Fabio Landoni; Andrea Papadia Journal: Gynecol Oncol Date: 2018-06-07 Impact factor: 5.482
Authors: Joyce N Barlin; Fady Khoury-Collado; Christine H Kim; Mario M Leitao; Dennis S Chi; Yukio Sonoda; Kaled Alektiar; Deborah F DeLair; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2012-02-22 Impact factor: 5.482
Authors: Maria B Schiavone; Oliver Zivanovic; Qin Zhou; Mario M Leitao; Douglas A Levine; Robert A Soslow; Kaled M Alektiar; Vicky Makker; Alexia Iasonos; Nadeem R Abu-Rustum Journal: Ann Surg Oncol Date: 2015-05-21 Impact factor: 5.344
Authors: Pamela T Soliman; Shannon N Westin; Shayan Dioun; Charlotte C Sun; Elizabeth Euscher; Mark F Munsell; Nicole D Fleming; Charles Levenback; Michael Frumovitz; Pedro T Ramirez; Karen H Lu Journal: Gynecol Oncol Date: 2017-05-18 Impact factor: 5.482
Authors: Brooke A Schlappe; Amy L Weaver; Jennifer A Ducie; Ane Gerda Zahl Eriksson; Sean C Dowdy; William A Cliby; Gretchen E Glaser; Robert A Soslow; Kaled M Alektiar; Vicky Makker; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao Journal: Gynecol Oncol Date: 2018-08-31 Impact factor: 5.482
Authors: Maria B Schiavone; Chiara Scelzo; Celeste Straight; Qin Zhou; Kaled M Alektiar; Vicky Makker; Robert A Soslow; Alexia Iasonos; Mario M Leitao; Nadeem R Abu-Rustum Journal: Ann Surg Oncol Date: 2017-03-03 Impact factor: 5.344
Authors: Ane Gerda Zahl Eriksson; Jen Ducie; Narisha Ali; Michaela E McGree; Amy L Weaver; Giorgio Bogani; William A Cliby; Sean C Dowdy; Jamie N Bakkum-Gamez; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao Journal: Gynecol Oncol Date: 2015-12-31 Impact factor: 5.482
Authors: Jessica D Arden; Kimberly Marvin; Hong Ye; Lena Juratli; Sirisha R Nandalur; Zaid Al-Wahab; Jayson Field; Jill Gadzinski; Joseph Anthony Rakowski; Barry Rosen; Maha Saada Jawad Journal: Adv Radiat Oncol Date: 2020-10-24
Authors: Jennifer J Mueller; Silvana Pedra Nobre; Kenya Braxton; Kaled M Alektiar; Mario M Leitao; Carol Aghajanian; Lora H Ellenson; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2020-04-01 Impact factor: 5.482
Authors: Sandra Russo; Joan L Walker; Jay W Carlson; Jeanne Carter; Leigh C Ward; Allan Covens; Edward J Tanner; Jane M Armer; Sheila Ridner; Sandi Hayes; Alphonse G Taghian; Cheryl Brunelle; Micael Lopez-Acevedo; Brittany A Davidson; Mark V Schaverien; Sharad A Ghamande; Michael Bernas; Andrea L Cheville; Kathleen J Yost; Kathryn Schmitz; Barbara Coyle; Jeannette Zucker; Danielle Enserro; Stephanie Pugh; Electra D Paskett; Leslie Ford; Worta McCaskill-Stevens Journal: Gynecol Oncol Date: 2020-11-04 Impact factor: 5.482